Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Early Phase 1
1(33.3%)
3Total
Phase 2(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07276542Phase 2Recruiting

Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.

Role: lead

NCT05214417Phase 2Unknown

Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy

Role: lead

NCT04285684Early Phase 1Completed

The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women

Role: lead

All 3 trials loaded